No Data
Buy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential Expansion
Buy Rating Affirmed: Vor Biopharma's Clinical and Financial Fortitude
Express News | JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Express News | Vor Biopharma Inc. : Oppenheimer Cuts Target Price to $10 From $15
Silvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market Potential
Vor Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 517.98% Wedbush → $11 Reiterates Outperform → Outperform 04/23/2024 517.98% Wedbush → $11 Reite